These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Successful rapid desensitization to intravenous etoposide using a 14-step protocol. Garcia Escallon S; Muniyappa PK; Subramanian S J Allergy Clin Immunol Pract; 2015; 3(4):627-8. PubMed ID: 25634221 [No Abstract] [Full Text] [Related]
10. [Treatment of stage I nonseminomatous testicular cancer with one cycle of adjuvant chemotherapy]. Corti Ortíz D; Fonerón Burgos A; Troncoso Schifferli L Actas Urol Esp; 1997; 21(10):961-3. PubMed ID: 9494159 [TBL] [Abstract][Full Text] [Related]
11. Six-step etoposide desensitization protocol: A pediatric, adolescent, and young adult case series. Stockton W; Lam F; Nguyen T; Nguyen T; Kirov I Pediatr Blood Cancer; 2021 Jan; 68(1):e28795. PubMed ID: 33155419 [TBL] [Abstract][Full Text] [Related]
12. [Indirect identification of hypersensitivity reaction to etoposide mediated by polysorbate 80]. Pantín C; Letellez J; Calzas J; Mohedano E Farm Hosp; 2018 Jan; 42(1):27-28. PubMed ID: 29306312 [No Abstract] [Full Text] [Related]
13. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. Pectasides D; Skarlos D; Dimopoulos AM; Farmakis D; Pectasides M; Fountzilas G; Aravantinos G Anticancer Res; 2003; 23(5b):4239-44. PubMed ID: 14666633 [TBL] [Abstract][Full Text] [Related]
14. [A case of testicular cancer in which complete response was achieved with chemotherapy including cisplatin, etoposide and bleomycin, and salvage surgery]. Uekado Y; Matsumoto M; Inagaki T; Shintani Y Gan To Kagaku Ryoho; 1994 Mar; 21(4):543-6. PubMed ID: 7510465 [TBL] [Abstract][Full Text] [Related]
15. Weakness and numbness after chemotherapy for metastatic non-seminoma testis: a new neurological complication. Verdonk RC; Enting RH; Janmaat M; Schroder CP; Sleijfer DT; Gietema JA Acta Oncol; 2008; 47(8):1596-8. PubMed ID: 18607855 [No Abstract] [Full Text] [Related]
16. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia. Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765 [TBL] [Abstract][Full Text] [Related]
17. [Hypersensitivity reaction to etoposide. A case report]. Mullera Martí M; Riba Solé M; Fernández de Gamarra Martínez E; Mangues Bafalluy MA Farm Hosp; 2014 May; 38(3):255-6. PubMed ID: 24951914 [TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity reactions to etoposide. A report of three cases and review of the literature. de Souza P; Friedlander M; Wilde C; Kirsten F; Ryan M Am J Clin Oncol; 1994 Oct; 17(5):387-9. PubMed ID: 8092107 [TBL] [Abstract][Full Text] [Related]
19. Metachronous bilateral testicular germ cell tumors: report of two cases. James FV; Kumar A; Jayaprakash PG; Mathews A J Cancer Res Ther; 2009; 5(3):206-7. PubMed ID: 19841564 [TBL] [Abstract][Full Text] [Related]
20. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group. Bamias A; Aravantinos G; Kastriotis I; Alivizatos G; Anastasiou I; Christodoulou C; Gyftaki R; Kalofonos HP; Dimopoulos MA Urol Oncol; 2011; 29(2):189-93. PubMed ID: 19362863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]